Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and their potential targets in multiple sclerosis therapy.

Olaf Stüve1, Thomas Prod'homme, Anthony Slavin

  • 1Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

Expert Opinion on Therapeutic Targets
|September 23, 2003
PubMed
Summary

Statins, cholesterol-lowering drugs, show promise for treating multiple sclerosis (MS). Their anti-inflammatory and neuroprotective effects suggest potential benefits beyond cholesterol reduction for MS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis.

Communications biology·2026
Same author

C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics.

Cellular and molecular neurobiology·2026
Same author

Peripheral complement C4 protein in schizophrenia: Association with gene copy number and immune cell subtypes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Why Is MS a More Frequent Complication of EBV Infection in Females?

Immunological reviews·2026
Same author

Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy.

Proceedings of the National Academy of Sciences of the United States of America·2026

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease with relapsing and chronic neurological impairment.
  • While CD4(+) T cells were traditionally implicated, other T cell subclasses and cell types contribute to MS pathogenesis.
  • Recurrent blood-brain barrier disruption and CNS inflammation are key in early MS, leading to irreversible demyelination and axonal damage.

Purpose of the Study:

  • To review experimental evidence on the potential clinical benefits of statins for multiple sclerosis (MS) patients.
  • To explore the anti-inflammatory and neuroprotective properties of statins relevant to MS treatment.

Main Methods:

  • Review of experimental evidence regarding statin efficacy in MS.
  • Analysis of statins' biological effects beyond cholesterol reduction.

Related Experiment Videos

Main Results:

  • Statins possess anti-inflammatory and neuroprotective properties.
  • These properties suggest potential therapeutic benefits for MS.
  • Statins offer an orally administered, safe alternative with fewer toxicities compared to current parenteral MS therapies.

Conclusions:

  • Statins may offer a beneficial treatment option for MS patients.
  • Further clinical investigation into statins for MS is warranted.
  • Statins represent a promising therapeutic avenue due to their multifaceted biological effects.